News archive
icon
Showing 776 results
May 2026
-
Media Release
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be… -
Media Release
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali® NATALEE oral presentation to… -
Story Access to Healthcare

Care Begins in Our Communities: 4 Things to Know About How We’re Investing in America’s Health
A year ago, we committed to investing $23 billion in America’s health over the next five years. Here’s a look at the impact we’ve made so far—plus a new initiative we’re launching in five cities to drive awareness and earlier detection of breast and prostate cancer.
-
Media Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto™ in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone in PSMAddition Deep PSA reduction higher in patients receiving Pluvicto… -
Story Education and Awareness

Stroke Awareness Month: What You Should Know About Your Stroke Risk
May is Stroke Awareness Month – a moment to pause and reflect on one of the leading causes of serious disability and death in the United States. Nearly 800,000 people in the US experience a stroke each year and every 40 seconds someone experiences one. Yet, despite how common stroke is, many people are still unaware of their risk – and what can be done to reduce it1.
-
Story Education and Awareness

A Conversation Women Wish They’d Had: Understanding the Risk of Breast Cancer Coming Back
Findings from the Breast Health & Experience Index reveal many women diagnosed with breast cancer want earlier, more honest conversations about the possibility of recurrence to help them feel more informed and empowered.
-
Media Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
April 2026
-
Media Release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North… -
Media Release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Media Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
March 2026
-
Story Hope

The Future of Treating Autoimmune Diseases: Science, Tech, & Patients Driving Progress
Today, 1 in 10 people in the United States have an autoimmune disease. Scientific innovations are opening pathways to help more patients.
-
Media Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 65
- › Next page